Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma

β-Adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chest 1991-11, Vol.100 (5), p.1254-1260
Hauptverfasser: Anderson, Sandra D., Rodwell, L.T., Toit, J. Du, Young, I.H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1260
container_issue 5
container_start_page 1254
container_title Chest
container_volume 100
creator Anderson, Sandra D.
Rodwell, L.T.
Toit, J. Du
Young, I.H.
description β-Adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the airways. Salmeterol is a highly lipophylic compound that is thought to bind to an exoreceptor near the β-receptor. The objective of this study was to compare the protective effect of salmeterol with albuterol against EIA. Exercise was performed 0.5, 2.5, 4.5, and 6.5 hours after administration of the active drugs. Subjects attended the laboratory on four days within six weeks and cycled for 8 min breathing dry compressed air. We studied 17 asthmatic subjects (aged 19 to 49 years) with moderate to severe EIA. Salmeterol (50 μg) or albuterol (200 μg) was given from a metered dose inhaler via a spacer (Volumatic). On the control day, the mean work load ± 1 SD was 174 ± 47 W, ventilation (ve) was 77.9 percent ± 11.2 percent of the target ventilation (60 percent maximum voluntary ventilation [MVV]), and heart rate was 170 ± 14 beats per minute. This intensity was maintained for all tests. FEV1 was measured before and after exercise and was expressed as percent predicted and as percentage of the preexercise value (percentage of fall). Thirty minutes after treatment, both drugs were effective in inhibiting EIA—percentage of fall in FEV1, 17 ± 12 after salmeterol; percentage of fall in FEV1, 15 ± 15 after albuterol. At 2.5, 4.5, and 6.5 hours, the reduction in FEV1 was significantly less (p
doi_str_mv 10.1378/chest.100.5.1254
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72445177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0012369216336716</els_id><sourcerecordid>72445177</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-dbaa4b432c2ba59a0c535959b54a2c3f06f1c4bf9f91572e410f5b3d7ac2071e3</originalsourceid><addsrcrecordid>eNp1kM1v1TAQxC0EKo_CnQtSDohbHl5_JA23qpRSqRJIwNnaOGviyomLnQD973GbJyoOnKzR7Oysf4y9BL4H2Z68tSPlZQ-c7_UehFaP2A46CbXUSj5mO85B1LLpxFP2LOdrXjR0zRE7guZEAMgdu3i_Jlx8nKvoqs8pLmTvVX9bXc4jBhqqLxgmWijFUPm5Ov9NyfpMtZ-H1Rb7NC_jhM_ZE4ch04vDe8y-fTj_evaxvvp0cXl2elVbBXqphx5R9UoKK3rUHXKrpe5012uFwkrHGwdW9a5zHehWkALudC-HFq3gLZA8Zm-2vTcp_ljL583ks6UQcKa4ZtMKpTS0bRnk26BNMedEztwkP2G6NcDNHTtzz64obrS5Y1cirw67136i4SGwwSr-64OP2WJwCedC4u-Y1rJpQD00j_77-MsnMnnCEMpSuXVexzXNGP5pfrdFqKD76SmZbD3NBW-J28UM0f__7D-Vh5yV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72445177</pqid></control><display><type>article</type><title>Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Anderson, Sandra D. ; Rodwell, L.T. ; Toit, J. Du ; Young, I.H.</creator><creatorcontrib>Anderson, Sandra D. ; Rodwell, L.T. ; Toit, J. Du ; Young, I.H.</creatorcontrib><description>β-Adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the airways. Salmeterol is a highly lipophylic compound that is thought to bind to an exoreceptor near the β-receptor. The objective of this study was to compare the protective effect of salmeterol with albuterol against EIA. Exercise was performed 0.5, 2.5, 4.5, and 6.5 hours after administration of the active drugs. Subjects attended the laboratory on four days within six weeks and cycled for 8 min breathing dry compressed air. We studied 17 asthmatic subjects (aged 19 to 49 years) with moderate to severe EIA. Salmeterol (50 μg) or albuterol (200 μg) was given from a metered dose inhaler via a spacer (Volumatic). On the control day, the mean work load ± 1 SD was 174 ± 47 W, ventilation (ve) was 77.9 percent ± 11.2 percent of the target ventilation (60 percent maximum voluntary ventilation [MVV]), and heart rate was 170 ± 14 beats per minute. This intensity was maintained for all tests. FEV1 was measured before and after exercise and was expressed as percent predicted and as percentage of the preexercise value (percentage of fall). Thirty minutes after treatment, both drugs were effective in inhibiting EIA—percentage of fall in FEV1, 17 ± 12 after salmeterol; percentage of fall in FEV1, 15 ± 15 after albuterol. At 2.5, 4.5, and 6.5 hours, the reduction in FEV1 was significantly less (p&lt;0.01) after salmeterol compared with albuterol. At 6.5 hours, the percentage of fall in FEV1 was 20 ± 10 after salmeterol and 36 ± 12 after albuterol. Salmeterol also had a more prolonged action as a bronchodilator and values for FEV1 were significantly higher compared with those on albuterol at 4.5 and 6.5 hours. At 6.5 hours, the FEV1 percent predicted was 96 ± 10 after salmeterol and 84 ± 12 after albuterol (p&lt;0.01). We conclude that the extent of protection against EIA and the bronchodilation induced by both drugs was similar, but that salmeterol has a longer duration of action compared with albuterol. The reason for its superior duration of action may be due to a slower clearance of the drug from the airways.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.100.5.1254</identifier><identifier>PMID: 1682113</identifier><identifier>CODEN: CHETBF</identifier><language>eng</language><publisher>Northbrook, IL: Elsevier Inc</publisher><subject>Administration, Inhalation ; Adrenergic beta-Agonists - therapeutic use ; Adult ; Albuterol - analogs &amp; derivatives ; Albuterol - therapeutic use ; Asthma, Exercise-Induced - prevention &amp; control ; Biological and medical sciences ; Exercise Test ; Female ; Forced Expiratory Volume - drug effects ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Respiratory system ; Salmeterol Xinafoate</subject><ispartof>Chest, 1991-11, Vol.100 (5), p.1254-1260</ispartof><rights>1991 The American College of Chest Physicians</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-dbaa4b432c2ba59a0c535959b54a2c3f06f1c4bf9f91572e410f5b3d7ac2071e3</citedby><cites>FETCH-LOGICAL-c415t-dbaa4b432c2ba59a0c535959b54a2c3f06f1c4bf9f91572e410f5b3d7ac2071e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5536614$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1682113$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anderson, Sandra D.</creatorcontrib><creatorcontrib>Rodwell, L.T.</creatorcontrib><creatorcontrib>Toit, J. Du</creatorcontrib><creatorcontrib>Young, I.H.</creatorcontrib><title>Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma</title><title>Chest</title><addtitle>Chest</addtitle><description>β-Adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the airways. Salmeterol is a highly lipophylic compound that is thought to bind to an exoreceptor near the β-receptor. The objective of this study was to compare the protective effect of salmeterol with albuterol against EIA. Exercise was performed 0.5, 2.5, 4.5, and 6.5 hours after administration of the active drugs. Subjects attended the laboratory on four days within six weeks and cycled for 8 min breathing dry compressed air. We studied 17 asthmatic subjects (aged 19 to 49 years) with moderate to severe EIA. Salmeterol (50 μg) or albuterol (200 μg) was given from a metered dose inhaler via a spacer (Volumatic). On the control day, the mean work load ± 1 SD was 174 ± 47 W, ventilation (ve) was 77.9 percent ± 11.2 percent of the target ventilation (60 percent maximum voluntary ventilation [MVV]), and heart rate was 170 ± 14 beats per minute. This intensity was maintained for all tests. FEV1 was measured before and after exercise and was expressed as percent predicted and as percentage of the preexercise value (percentage of fall). Thirty minutes after treatment, both drugs were effective in inhibiting EIA—percentage of fall in FEV1, 17 ± 12 after salmeterol; percentage of fall in FEV1, 15 ± 15 after albuterol. At 2.5, 4.5, and 6.5 hours, the reduction in FEV1 was significantly less (p&lt;0.01) after salmeterol compared with albuterol. At 6.5 hours, the percentage of fall in FEV1 was 20 ± 10 after salmeterol and 36 ± 12 after albuterol. Salmeterol also had a more prolonged action as a bronchodilator and values for FEV1 were significantly higher compared with those on albuterol at 4.5 and 6.5 hours. At 6.5 hours, the FEV1 percent predicted was 96 ± 10 after salmeterol and 84 ± 12 after albuterol (p&lt;0.01). We conclude that the extent of protection against EIA and the bronchodilation induced by both drugs was similar, but that salmeterol has a longer duration of action compared with albuterol. The reason for its superior duration of action may be due to a slower clearance of the drug from the airways.</description><subject>Administration, Inhalation</subject><subject>Adrenergic beta-Agonists - therapeutic use</subject><subject>Adult</subject><subject>Albuterol - analogs &amp; derivatives</subject><subject>Albuterol - therapeutic use</subject><subject>Asthma, Exercise-Induced - prevention &amp; control</subject><subject>Biological and medical sciences</subject><subject>Exercise Test</subject><subject>Female</subject><subject>Forced Expiratory Volume - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory system</subject><subject>Salmeterol Xinafoate</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1v1TAQxC0EKo_CnQtSDohbHl5_JA23qpRSqRJIwNnaOGviyomLnQD973GbJyoOnKzR7Oysf4y9BL4H2Z68tSPlZQ-c7_UehFaP2A46CbXUSj5mO85B1LLpxFP2LOdrXjR0zRE7guZEAMgdu3i_Jlx8nKvoqs8pLmTvVX9bXc4jBhqqLxgmWijFUPm5Ov9NyfpMtZ-H1Rb7NC_jhM_ZE4ch04vDe8y-fTj_evaxvvp0cXl2elVbBXqphx5R9UoKK3rUHXKrpe5012uFwkrHGwdW9a5zHehWkALudC-HFq3gLZA8Zm-2vTcp_ljL583ks6UQcKa4ZtMKpTS0bRnk26BNMedEztwkP2G6NcDNHTtzz64obrS5Y1cirw67136i4SGwwSr-64OP2WJwCedC4u-Y1rJpQD00j_77-MsnMnnCEMpSuXVexzXNGP5pfrdFqKD76SmZbD3NBW-J28UM0f__7D-Vh5yV</recordid><startdate>19911101</startdate><enddate>19911101</enddate><creator>Anderson, Sandra D.</creator><creator>Rodwell, L.T.</creator><creator>Toit, J. Du</creator><creator>Young, I.H.</creator><general>Elsevier Inc</general><general>American College of Chest Physicians</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19911101</creationdate><title>Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma</title><author>Anderson, Sandra D. ; Rodwell, L.T. ; Toit, J. Du ; Young, I.H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-dbaa4b432c2ba59a0c535959b54a2c3f06f1c4bf9f91572e410f5b3d7ac2071e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Administration, Inhalation</topic><topic>Adrenergic beta-Agonists - therapeutic use</topic><topic>Adult</topic><topic>Albuterol - analogs &amp; derivatives</topic><topic>Albuterol - therapeutic use</topic><topic>Asthma, Exercise-Induced - prevention &amp; control</topic><topic>Biological and medical sciences</topic><topic>Exercise Test</topic><topic>Female</topic><topic>Forced Expiratory Volume - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory system</topic><topic>Salmeterol Xinafoate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anderson, Sandra D.</creatorcontrib><creatorcontrib>Rodwell, L.T.</creatorcontrib><creatorcontrib>Toit, J. Du</creatorcontrib><creatorcontrib>Young, I.H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anderson, Sandra D.</au><au>Rodwell, L.T.</au><au>Toit, J. Du</au><au>Young, I.H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>1991-11-01</date><risdate>1991</risdate><volume>100</volume><issue>5</issue><spage>1254</spage><epage>1260</epage><pages>1254-1260</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><coden>CHETBF</coden><abstract>β-Adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the airways. Salmeterol is a highly lipophylic compound that is thought to bind to an exoreceptor near the β-receptor. The objective of this study was to compare the protective effect of salmeterol with albuterol against EIA. Exercise was performed 0.5, 2.5, 4.5, and 6.5 hours after administration of the active drugs. Subjects attended the laboratory on four days within six weeks and cycled for 8 min breathing dry compressed air. We studied 17 asthmatic subjects (aged 19 to 49 years) with moderate to severe EIA. Salmeterol (50 μg) or albuterol (200 μg) was given from a metered dose inhaler via a spacer (Volumatic). On the control day, the mean work load ± 1 SD was 174 ± 47 W, ventilation (ve) was 77.9 percent ± 11.2 percent of the target ventilation (60 percent maximum voluntary ventilation [MVV]), and heart rate was 170 ± 14 beats per minute. This intensity was maintained for all tests. FEV1 was measured before and after exercise and was expressed as percent predicted and as percentage of the preexercise value (percentage of fall). Thirty minutes after treatment, both drugs were effective in inhibiting EIA—percentage of fall in FEV1, 17 ± 12 after salmeterol; percentage of fall in FEV1, 15 ± 15 after albuterol. At 2.5, 4.5, and 6.5 hours, the reduction in FEV1 was significantly less (p&lt;0.01) after salmeterol compared with albuterol. At 6.5 hours, the percentage of fall in FEV1 was 20 ± 10 after salmeterol and 36 ± 12 after albuterol. Salmeterol also had a more prolonged action as a bronchodilator and values for FEV1 were significantly higher compared with those on albuterol at 4.5 and 6.5 hours. At 6.5 hours, the FEV1 percent predicted was 96 ± 10 after salmeterol and 84 ± 12 after albuterol (p&lt;0.01). We conclude that the extent of protection against EIA and the bronchodilation induced by both drugs was similar, but that salmeterol has a longer duration of action compared with albuterol. The reason for its superior duration of action may be due to a slower clearance of the drug from the airways.</abstract><cop>Northbrook, IL</cop><pub>Elsevier Inc</pub><pmid>1682113</pmid><doi>10.1378/chest.100.5.1254</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0012-3692
ispartof Chest, 1991-11, Vol.100 (5), p.1254-1260
issn 0012-3692
1931-3543
language eng
recordid cdi_proquest_miscellaneous_72445177
source MEDLINE; Alma/SFX Local Collection
subjects Administration, Inhalation
Adrenergic beta-Agonists - therapeutic use
Adult
Albuterol - analogs & derivatives
Albuterol - therapeutic use
Asthma, Exercise-Induced - prevention & control
Biological and medical sciences
Exercise Test
Female
Forced Expiratory Volume - drug effects
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Respiratory system
Salmeterol Xinafoate
title Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A46%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Duration%20of%20Protection%20by%20Inhaled%20Salmeterol%20in%20Exercise-induced%20Asthma&rft.jtitle=Chest&rft.au=Anderson,%20Sandra%20D.&rft.date=1991-11-01&rft.volume=100&rft.issue=5&rft.spage=1254&rft.epage=1260&rft.pages=1254-1260&rft.issn=0012-3692&rft.eissn=1931-3543&rft.coden=CHETBF&rft_id=info:doi/10.1378/chest.100.5.1254&rft_dat=%3Cproquest_cross%3E72445177%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72445177&rft_id=info:pmid/1682113&rft_els_id=S0012369216336716&rfr_iscdi=true